Sometimes a startup takes longer to exit than the fund's life allows. The company is doing well, but the clock runs out. A continuation fund solves this problem. It gives the general partner (GP) more time and lets limited partners (LPs) get cash back early.
This is a big part of the GP-led secondary market. It is not just about selling bad assets. It is often about keeping the best ones. Here is how the mechanics work, in simple terms.
| Feature | Traditional Fund Exit | Continuation Fund Exit |
|---|---|---|
| Timing | Sell before fund life ends (usually 10 years) | Move asset to a new vehicle, reset the clock |
| LP Choice | Must take proceeds, often reinvest elsewhere | Choose between cash out or roll over into new fund |
| Asset Quality | Mixed; selling what is ready | Tends to be high-quality winners needing more time |
| Manager (GP) Role | Winds down, returns capital | Stays active, continues to manage the asset |
Think of it like a relay race. The first runner (the original fund) is near the finish line. Instead of stopping, they hand the baton to a fresh runner (the continuation fund) on the same team.
Imagine a VC fund invested early in a fintech startup. After 9 years, the startup is worth $500 million but needs 3 more years to go public. The fund's life ends in 12 months. A continuation fund buys the stake, holds it for 3 years, and then sells after the IPO.
The LPs who need cash take $500 million now. The LPs who stay get shares in the new fund.
A continuation fund is a new bucket. It holds one or a few assets from an older bucket.
It gives GPs more time to create value. It gives LPs a clear choice: cash today, or shares tomorrow.
The Big Price Discussion
Price is the trickiest part of any GP-led deal. The GP sets the price for the asset. New investors, called secondary buyers, also bid on it. This creates a tension. The GP wants a high price to show past success. The buyer wants a low price for future returns.
| Stakeholder | Primary Goal | Biggest Fear |
|---|---|---|
| Selling LPs | Get fair, transparent price for their stake | Leaving money on the table |
| Rolling LPs | Avoid dilution, keep exposure to winner | Overpaying due to GP bias |
| New Secondary Buyers | Buy at a discount to intrinsic value | GP overstating the asset's prospects |
| GP (Manager) | Raise new vehicle, align all parties | Conflict of interest accusations |
The solution is often a lead investor. This is a big secondary firm that sets the price. Their due diligence acts as a stamp of approval for everyone else. It makes the deal feel more fair.
A GP wants to move a SaaS company to a continuation fund at a $200 million value. A lead investor comes in, does deep research, and says the fair value is $190 million. The final deal happens at $192 million. The lead investor's work gave all LPs confidence in the price.
Why LPs Say Yes or No
LPs get a package of documents. They have to decide in a few weeks. This is called the election period. It can feel rushed. The two main choices are simple: sell everything or roll everything. Some deals offer a mix.
| LP Type | Typical Action | Reasoning |
|---|---|---|
| Cash-needy pension fund | Sell full stake | Need liquidity to pay retirees; mandate requires distributions |
| Long-term endowment | Roll full stake | Believe in the asset; no immediate cash needs; trust the GP |
| Over-allocated fund of funds | Sell partial stake | Reduce venture exposure but keep some upside |
| Small family office | Sell full stake | Cannot afford legal costs to review complex terms; take the cash |
GPs often give a sweetener to LPs who roll over. Maybe no management fees for a year. Or a piece of the GP's own profit share. This is to make the roll option more attractive and keep the deal aligned.
LPs must decide in a short window. The default is usually to sell, not to roll.
GPs need a high roll rate to show the market the deal is healthy. A low roll rate signals trouble.
The Legal and Structural Setup
A continuation fund is a fresh legal entity. It sits side by side with the old fund. The GP manages both. The old fund gets cash from the new fund to distribute to LPs. This is not a paper shuffle. Real money moves.
| Term | What It Means in Plain English | Why It Matters |
|---|---|---|
| Staple | Requiring roll-over LPs to commit to the GP's next main fund | Can force a tough choice; often disliked by LPs |
| GP Commit | GP puts own money into the continuation fund | Shows skin in the game; aligns interests |
| Fee Waiver | No management fees on rolled capital for a short period | Sweetener to encourage rolling |
| Status Quo | Option where LP does nothing, often treated as a sale | Inertia usually leads to an exit; GPs design this carefully |
The process is a negotiation. GPs want a clean break. LPs want clarity. Lawyers draft hundreds of pages. At the center is a simple promise: the new fund will hold this asset until the right exit moment.
A GP moves a biotech firm to a continuation fund. The GP commits 5% of the new fund's size from their own pocket. They also waive management fees for the first 18 months. These two moves convince 85% of LPs to roll over their stakes.
The Rise of the Secondary Market
The volume of GP-led deals has grown fast. It used to be a rare tool. Now it is a standard part of the venture playbook. Big secondary funds have raised billions to buy these assets. They act like private equity for venture portfolios.
This gives the whole venture ecosystem more flexibility. A startup can stay private longer. A GP can manage a portfolio more like a company, holding onto crown jewels. LPs get a new path to liquidity.
| Driver | Impact on Market |
|---|---|
| Longer time to IPO | Companies stay private 12+ years; funds need more time |
| Record dry powder | Secondary funds have over $200 billion waiting to invest globally |
| LP education | Limited partners now understand the playbook and negotiate better terms |
| Large legacy assets | Funds hold billion-dollar positions that are hard to sell in open market |
The market used to be a distress sale signal. Not anymore. High-quality GPs use continuation funds. It is a badge of confidence. They are saying, "This asset is too good to sell now."
GP-led deals were once seen as rescue missions for struggling assets.
Today, the strongest deals feature trophy assets that GPs actively want to keep managing.
The Risks No One Talks About
Not every deal works. Some assets move to a continuation fund and still fail. The extra time does not fix a broken business model. Also, fees can eat into returns. Management fees on the old fund and the new fund can stack up.
Conflicts of interest are real. The GP is on both sides of the trade: they price the asset they sold, and now they buy it for the new vehicle. Strong independent advice and a lead investor are the only checks against this.
A clean energy company was moved to a continuation fund at a $300 million value. Two years later, technology shifts made its product outdated. The asset sold for $80 million. The extra time did not save it. The GP's judgment was simply wrong.
How to Evaluate a Deal as an LP
LPs should look at a few simple things. First, who is the lead buyer? A well-known secondary firm adds safety. Second, what is the GP putting in? A large personal check is a good sign. Third, what do the independent legal advisors say?
Price is important but not everything. The structure of the deal matters more. Look for clean terms. Avoid deals where the GP gets rich on fees before the LP gets a return.
Look for a reputable lead buyer who sets the price.
Check the GP co-invest amount. It should be meaningful, not symbolic.
Key Takeaways
| Key Point | What It Means | Action Item |
|---|---|---|
| Continuation funds reset the clock | They allow GPs to hold assets beyond a fund's life | View them as a normal tool, not a red flag |
| Lead buyers set the price floor | Their due diligence protects all LPs from bad pricing | Always check who the lead buyer is and their reputation |
| LPs get a binary choice | Sell for cash now or roll equity into the new vehicle | Read the election notice carefully; the default option is often a sale |
| Conflict of interest is the biggest risk | GP is on both sides of the transaction | Demand independent fairness opinions and clear GP co-investment |
| The market is now mainstream | High-quality GPs use these for trophy assets | Do not automatically assume a continuation fund means trouble |
| Fees can compound | You can pay fees on the old fund and the new fund simultaneously | Check for fee waivers or offsets to avoid double-charging |